Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534302 | 0.97 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4531951 | 0.94 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4529268 | 0.83 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL15238270 | 0.83 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4536383 | 0.83 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4542644 | 0.82 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4537939 | 0.81 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4540536 | 0.81 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL27928865 | 0.80 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL27911065 | 0.80 | HCRTR1 (0.69) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | claimed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | claimed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | claimed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | claimed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | claimed |
| EP-4596051-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | Pharmacosmos Holding A/s (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| EP-2968291-B1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | PHARMACOSMOS HOLDING AS (DK) | 2025-04-16 | — | — | EP | disclosed |
| US-20240109906-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-8691830-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8598197-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8598186-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2013163239-A1 | SYNTHESIS OF LACTAMS | TAVARES FRANCIS XAVIER (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| US-20130237533-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | HCRTR1 4634/4885HCRTR2 4518/4885 |
| US-20240109906-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | HCRTR1 4634/4885HCRTR2 4518/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | HCRTR1 2438/4885HCRTR2 3029/4885 |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | HCRTR1 4181/4885HCRTR2 4302/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | HCRTR1 4364/4885HCRTR2 4514/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | HCRTR1 4172/4885HCRTR2 4106/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20130237533-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | HCRTR1 4634/4885HCRTR2 4518/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | HCRTR1 4634/4885HCRTR2 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.